Adisa Rahmat A, Choudhary Mohammed I, Adewoye Elsie O, Olorunsogo Olufunso O
Laboratories for Biomembrane Research and Biotechnology, Department of Biochemistry, College of Medicine, University of Ibadan, Nigeria.
Afr J Tradit Complement Altern Med. 2010 Apr 3;7(3):185-94. doi: 10.4314/ajtcam.v7i3.54774.
Increasing incidences of diabetes in Africa has prompted the search for safe and readily available alternative herbal remedies for the treatment of diabetes mellitus. Cnestis ferruginea was extracted with methanol and ethylacetate and the extracts obtained were tested for hypoglycaemic activities in streptozotocin (STZ)-induced diabetic rats and mice. The extracts (250 mg/kg body weight) were administered orally for 10 consecutive days to STZ-induced diabetic rats while a single dose (250 mg/kg body weight) of the extracts were administered to STZ-induced diabetic mice. Fasting blood glucose (FBG) levels were determined in the two groups of animals after extract administration. There was significant reduction in FBG (P< 0.005) by MCF and ECF within 4 hrs of extract administration in a time- dependent manner. Furthermore, administration of MCF and ECF for 10 days significantly lowered FBG in STZ diabetic rats (P<0.005) by 74% and 68%, respectively, whereas, glibenclamide - a standard antidiabetic drug reduced FBG by 60%. The levels of serum creatinine, urea, triglyceride, total cholesterol, total protein and level of lipid peroxidation were also evaluated. The extracts reduced significantly (P<0.005) the elevated levels of serum ALT and AST in diabetic treated rats. Similarly, both extracts significantly lowered (P<0.005) the levels of serum creatinine, urea, total cholesterol, triglyceride and thiobarbituric acid reactive species (TBARS).These results suggest that Cnestis ferruginea leaves contain a highly potent hypoglycaemic principle and could be a potential source for isolation of new orally active antihyperglycaemic compounds for attenuating secondary complications of diabetes such as atherosclerosis, liver and renal dysfunction.
非洲糖尿病发病率的不断上升促使人们寻找安全且易于获取的替代草药疗法来治疗糖尿病。用甲醇和乙酸乙酯对铁锈色金合欢进行提取,并对所得提取物在链脲佐菌素(STZ)诱导的糖尿病大鼠和小鼠中进行降血糖活性测试。将提取物(250毫克/千克体重)连续10天口服给予STZ诱导的糖尿病大鼠,而将单剂量(250毫克/千克体重)的提取物给予STZ诱导的糖尿病小鼠。在给予提取物后,测定两组动物的空腹血糖(FBG)水平。MCF和ECF在提取物给药后4小时内以时间依赖性方式使FBG显著降低(P<0.005)。此外,给予MCF和ECF 10天可使STZ糖尿病大鼠的FBG分别显著降低(P<0.005)74%和68%,而标准抗糖尿病药物格列本脲使FBG降低了60%。还评估了血清肌酐、尿素、甘油三酯、总胆固醇、总蛋白水平以及脂质过氧化水平。提取物显著降低(P<0.005)了糖尿病治疗大鼠中升高的血清ALT和AST水平。同样,两种提取物均显著降低(P<0.005)了血清肌酐、尿素、总胆固醇、甘油三酯和硫代巴比妥酸反应性物质(TBARS)的水平。这些结果表明,铁锈色金合欢叶含有高效的降血糖成分,可能是分离新型口服活性抗高血糖化合物的潜在来源,以减轻糖尿病的继发性并发症,如动脉粥样硬化、肝脏和肾脏功能障碍。